Cara | $8,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Earlyasset | $2,000,000 | (Apr 2, 2026)
Certified by Founder
Lodge
Altesa BioSciences, Inc.
start up
United States
- Atlanta, GA
- 20/02/2026
- Series B
- $75,000,000
Altesa is an innovative, clinical-stage pharmaceutical company dedicated to preventing and treating the leading cause of COPD and asthma exacerbations -- namely viral respiratory infections -- starting with rhinovirus, the most common respiratory virus on the planet.
Our goal is to disrupt the COPD treatment paradigm by targeting the upstream cause of acute respiratory exacerbations -- not accept the status quo of managing the long term downstream consequences like chronic inflammation, hospitalizations and even death.
- Industry Biotechnology Research
- Website https://www.altesabio.com/
- LinkedIn https://www.linkedin.com/company/altesa-biosciences/
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Variance | $21,500,000 | (Apr 2, 2026)
TippingPoint Biosciences | $4,500,000 | (Apr 2, 2026)
Quantcore | $3,318,962 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)
Semarion | $3,800,000 | (Apr 2, 2026)
Via Separations | $36,000,000 | (Apr 2, 2026)
Stedi | $50,000,000 | (Mar 31, 2026)